In summary, our study manifested the high effectiveness of the combination regimen with anti‐PD‐1 antibody, trastuzumab, and chemotherapy in patients with HER2‐positive GC in a real‐world setting for the first time. This evidence concerns the gene ERBB2 and gastric cancer.